F. Bourdel

Phase I Population Pharmacokinetic Assessment of the Oral Bromodomain Inhibitor OTX015 in Patients with Haematologic Malignancies

B. Quesnel, P. Hérait, A. Stathis, 2016, Clinical Pharmacokinetics.

A Phase 1 Study of the BET-Bromodomain Inhibitor OTX015 in Patients with Non-Leukemic Hematologic Malignancies

G. Salles, M. Gleeson, P. Hérait, 2014 .

Abstract LB-231: A phase I pharmacokinetic study of OTX015 for the treatment of patients with hematologic malignancies

H. Dombret, P. Hérait, Elodie Odore, 2014 .

Abstract CT231: BET-bromodomain inhibitor OTX015 shows clinically meaningful activity at nontoxic doses: interim results of an ongoing phase I trial in hematologic malignancies

A. Palumbo, H. Dombret, B. Quesnel, 2014 .

A Phase 1 Study of the BET-Bromodomain Inhibitor OTX015 in Patients with Advanced Acute Leukemia

H. Dombret, B. Quesnel, P. Hérait, 2014 .

β-Amyloid protein aggregation: its implication in the physiopathology of Alzheimer's disease

F. Bourdel, M. Reboud-Ravaux, S. Viale, 2001 .